Table 1. Agents in current clinical trials for IPF.
NCT, National Clinical Trial (www.clinicaltrials.gov)
| Agent | Target | Purported mechanism of action | NCT Identifier |
|---|---|---|---|
| Tralokinumab | IL-13 | Decreases expression of TGF-β and macrophage CCL2 | NCT01629667 |
| Lebrikizumab | IL-13 | (as above) | NCT01872689 |
| FG-3019 | CTGF | Decreases CTGF-mediated pro-fibrotic actions on fibroblasts | NCT01890265 |
| Simtuzumab | LOXL2 | Decreases extracellular matrix cross-linking | NCT01769196 |
| STX-100 | Integrin αvβ6 | Decreases activation of latent TGF-β | NCT01371305 |
| BMS-986020 | LPA1 receptor | Decreases vascular leak and fibroblast recruitment | NCT01766817 |
| Rituximab | CD20 | Decreases contribution of antibody-mediated autoimmunity | NCT01969409 |
| Carbon Monoxide | Inflammation | Anti-inflammatory, may also suppress fibroblast proliferation | NCT01214187 |
| Azithromycin | Bacteria, inflammation | Antimicrobial, immunomodulatory | NCT02173145 |
| Cotrimoxazole | Pneumocystis jiroveci, bacteria | Antimicrobial | NCT01777737 |